Search

Your search keyword '"C TERENZI"' showing total 2 results
Start Over Author "C TERENZI" Journal cell metabolism
2 results on '"C TERENZI"'

1. SGLT-2 Inhibitors and Regenerative Cell Exhaustion

Author

Daniella C. Terenzi, Subodh Verma, and David A. Hess

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Physiology, Cell, MEDLINE, Placebo treatment, Type 2 diabetes, 03 medical and health sciences, 0302 clinical medicine, Glucosides, Sodium-Glucose Transporter 2, Internal medicine, Empagliflozin, Medicine, Humans, Hypoglycemic Agents, In patient, Benzhydryl Compounds, Molecular Biology, Sodium-Glucose Transporter 2 Inhibitors, business.industry, Stem Cells, Cell Biology, medicine.disease, 030104 developmental biology, medicine.anatomical_structure, Diabetes Mellitus, Type 2, business, 030217 neurology & neurosurgery
Abstract

In response to the Letter by Fadini, Hess et al. discuss the interpretation of their data and the details of the multiparametric analyses employed to measure the changes in circulating provascular cell content in patients with type 2 diabetes receiving empagliflozin compared to placebo treatment.

Published
2020

2. SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus

Author

Justin Z. Trac, Ori D. Rotstein, Tamique Mason, Deepak L. Bhatt, Andrew T. Yan, Bernard Zinman, Lawrence A. Leiter, David A. Hess, Hwee Teoh, Sandra Sabongui, Mohammed Al-Omran, Adrian Quan, Kim A. Connelly, C. David Mazer, Natasha Dhingra, Daniella C. Terenzi, and Subodh Verma

Subjects
0301 basic medicine, Adult, medicine.medical_specialty, Cardiotonic Agents, Physiology, Cell, Coronary Artery Disease, Granulocyte, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Glucosides, Internal medicine, Diabetes mellitus, medicine, Empagliflozin, Humans, Regeneration, Progenitor cell, Benzhydryl Compounds, Molecular Biology, Sodium-Glucose Transporter 2 Inhibitors, Myeloid Progenitor Cells, Aged, Aged, 80 and over, business.industry, Regeneration (biology), Type 2 Diabetes Mellitus, Cell Biology, Middle Aged, medicine.disease, 3. Good health, 030104 developmental biology, Endocrinology, medicine.anatomical_structure, chemistry, Diabetes Mellitus, Type 2, Cardiovascular Diseases, business, 030217 neurology & neurosurgery, EMPA
Abstract

Hess et al. quantified circulating aldehyde dehydrogenase-expressing (ALDHhi) cell subsets in people with T2DM given either empagliflozin (EMPA) or placebo. EMPA treatment increased circulating pro-angiogenic CD133+ progenitor cells, decreased pro-inflammatory ALDHhi granulocyte precursors, and increased ALDHhi monocytes with M2 polarization. EMPA treatment improved T2DM-associated "regenerative cell depletion" contributing to enhanced vascular health.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results